NCT00943423Active, not recruitingPhase 3
PET Scan in Planning Treatment in Patients Undergoing Combination Chemotherapy For Stage IA or Stage IIA Hodgkin Lymphoma
A Randomised Phase III Trial to Determine the Role of FDG-PET Imaging in Clinical Stages IA/IIA Hodgkin's Disease
Source: ClinicalTrials.gov · Last updated 30 Nov 2023
Brief summary (registry, in English)
RATIONALE: A PET scan may help doctors learn how the cancer responded to combination chemotherapy and whether radiation therapy is also required. PURPOSE: This randomized phase III trial is studying giving a PET scan to see how well it works in deciding whether patients who have received combination chemotherapy for stage IA or stage IIA Hodgkin lymphoma also need radiation therapy.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 602 (actual)
- First submitted
- 20 Jul 2009
- Start date
- Jul 2003
- Primary completion date
- Jul 2014
- Lead sponsor
- University College, London
- Diseases
- Hodgkin lymphoma, Childhood cancers
- NCT number
- NCT00943423
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 602
- From Jul 2003 to the primary completion date, Jul 2014
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- DISEASE CHARACTERISTICS:
- Histologically confirmed Hodgkin Lymphoma
- Stage IA or IIA disease
- No stage IA Hodgkin lymphoma with no clinical or CT evidence of disease after diagnostic biopsy
- Above the diaphragm with no mediastinal bulk, defined as maximum transverse diameter of mediastinal mass
- Internal thoracic diameter at level of D5/6 interspace \> 0.33
- Bulky disease at other sites, defined as nodal mass with transverse diameter ≥ 10 cm allowed
- PATIENT CHARACTERISTICS:
- Not pregnant or nursing
- Fertile patients must use effective contraception during and for ≥ 6 months
- No prior malignancy except appropriately treated basal cell carcinoma of the skin or carcinoma in situ of the cervix
- No severe underlying illness considered to make the trial therapy hazardous (i.e., severe heart disease or lung fibrosis)
- Willing to travel to the nearest PET scan center
- Able to comply with protocol follow-up arrangements
- PRIOR CONCURRENT THERAPY:
- No prior treatment for Hodgkin lymphoma
- No contraindications to chemotherapy or radiotherapy
Age in the registry: 16 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Christie Hospital Coordinator of this site? Confirm its status | Manchester | United Kingdom | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.